Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease

NCT06774040 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral Arterial Disease

Interventions

DRUG: Etribnabdione 25 mg BID
DRUG: Etribnabdione 50 mg BID

Sponsor

VivaCell Biotechnology España